Mucinous colorectal adenocarcinoma:clinical pathology and treatment options

Mucinous colorectal adenocarcinoma is a distinct subtype of colorectal cancer(CRC)characterized by the pres-ence of abundant extracellular mucin which accounts for at least 50%of the tumor volume.Mucinous colorectal adenocarcinoma is found in 10%-20%of CRC patients and occurs more commonly in female and younger patients.Moreover,mucinous colorectal adenocarcinoma is more frequently located in the proximal colon and diagnosed at an advanced stage.Based on its molecular context,mucinous colorectal adenocarcinoma is associated with the over-expression of mucin 2(MUC2)and mucin 5AC(MUC5AC)proteins.At the same time,it shows higher mutation rates in the fundamental genes of the RAS/MAPK and PI3K/Akt/mTOR pathways.Mucinous colorectal adenocarcinoma also shows higher rates of microsatellite instability(MSI)than non-mucinous colorectal adenocarcinoma which might correlate it with Lynch syndrome and the CpG island methylator phenotype.The prognosis of mucinous colorectal adenocarcinoma as to non-mucinous colorectal adenocarcinoma is debatable.Further,the impaired responses of mucinous colorectal adenocarcinoma to palliative or adjuvant chemotherapy warrant more studies to be performed for a specialized treatment for these patients.In this review,we discuss the molecular background and histopathol-ogy of mucinous colorectal adenocarcinoma,and provide an update on its prognosis and therapeutics from recent literatures.